NANOCO GROUP PLC — Regulatory Filings 2014

Jun 9, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1627J

Nanoco Group PLC

09 June 2014

For immediate release	9 June 2014

NANOCO GROUP PLC

("Nanoco" or "the Company")

Receives Technology Strategy Board Grant for Bio-imaging

Nanoco Group plc (AIM: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, announces that it has been awarded a further £308,000 grant to support its research at University College London (UCL) into the use of cadmium-free quantum dots in the in-vivo imaging of cancer.

The grant has been awarded by the Technology Strategy Board (TSB), the UK's innovation agency, under its Biomedical Catalyst funding programme. UCL will also receive a TSB grant under the Biomedical Catalyst programme to support the project.

Nanoco and UCL began joint research work in 2011 in which the fluorescence of Nanoco quantum dots is being used to pinpoint malignant lymph nodes to guide surgeons in the removal of cancerous tissue. Other materials have already been used in this way in clinical practice but Nanoco quantum dots offer the major advantage of fluorescing for a longer period of time, giving surgeons a greater opportunity to remove cancer cells.

The TSB funding announced today will be used to support the next stage of the joint research programme.

Michael Edelman, Nanoco's Chief Executive Officer, said: "We're delighted to receive this grant award from the Technology Strategy Board for our exciting work with University College London in cancer imaging. Our work to date shows that the sustained fluorescence achievable with Nanoco quantum dots has the potential to give surgeons a much greater window than currently available for the removal of cancer cells.

"We look forward to continuing this research with the ultimate objective of our technology becoming part of a commercially available bio-imaging product. This bio-imaging research highlights the versatility of our core cadmium-free quantum dot technology and its multiple potential commercial applications of which the display sector is our lead focus."

For further information please contact:

### Nanoco	### + 44 (0) 161 603 7900
Michael Edelman, Chief Executive Officer
Colin White, Chief Financial Officer
Canaccord Genuity - Nomad and Joint Broker	+44 (0) 20 7523 8000
Simon Bridges
Cameron Duncan
Liberum Capital - Joint Broker	+44 (0) 20 3100 2000
Simon Atkinson
Richard Bootle
### Buchanan	### + 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles

Notes for editors:

About Nanoco Group plc

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nano-materials for use in multiple applications including LCD displays, lighting, solar cells and bio-imaging. In the display market, it has an exclusive manufacturing and marketing licensing agreement with The Dow Chemical Company.

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development offices in Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

Nanoco began trading on the AIM market of the London Stock Exchange in May 2009 under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCFLMBTMBBMBPI